Treatment of Unresectable Differentiated Thyroid Carcinoma With Upfront External Radiotherapy and Salvage Surgery: A STROBE-Compliant Retrospective Cohort Study

Introduction In patients with unresectable Differentiated thyroid cancer (DTC), the use of external beam radiation therapy (EBRT), leads mostly to palliation. Our aim is to define the role of upfront EBRT, followed or not by salvage surgery, on Progression-free survival (PFS) or Overall survival (OS) in patients with DTC. Methods This is a cohort study of patients with initially unresectable DTC who received EBRT. Cohort A received EBRT followed by rescue surgery and cohort B, EBRT only. The Kaplan-Meier method and Cox model were employed for survival analysis. Results Thirty-three patients were included; 69.6% females and 30.3% males. Mean age was 60.6 and mean tumor diameter was 10.4 cm; 17 and 16 patients were included in cohorts A and B, respectively. Belonging to cohort A (Hazard ratio [HR] 0.177, 95% CI 0.05–0.7) and use of intensity modulated radiotherapy (HR 0.177, 95% CI 0.03–1.08) were associated to better PFS, while high-risk histopathology (HR 6.6, 95% CI 0.9–50) and EBRT dose (HR 1.05, 95% CI 1.01–1.08) were independently associated with lower PFS. Patients from cohort A (HR 0.061, 95% CI 0.01–0.3) had improved OS, while high-risk histopathology (HR 5.7, 95% CI 1.1–28.6) and EBRT dose (HR 1.05, 95% CI 1.01–1.09) were independently associated to worse OS. Conclusion EBRT, and when feasible, salvage surgery, should be an integral part of the therapeutic strategy in initially unresectable DTC.

[1]  G. Rinaldi,et al.  Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. , 2019, European journal of cancer.

[2]  J. Shah,et al.  Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. , 2019, Thyroid : official journal of the American Thyroid Association.

[3]  J. Sosa,et al.  Evolving Understanding of the Epidemiology of Thyroid Cancer. , 2019, Endocrinology and metabolism clinics of North America.

[4]  J. Shah,et al.  NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Tomoaki Tanaka,et al.  Usefulness of Stereotactic Radiotherapy Using the CyberKnife for Patients with Inoperable Locoregional Recurrences of Differentiated Thyroid Cancer , 2018, World Journal of Surgery.

[6]  N. Besic,et al.  Locoregional Disease Control After External Beam Radiotherapy in 91 Patients with Differentiated Thyroid Carcinoma and pT4 Tumor Stage - A Single Institution Experience , 2018, Radiology and oncology.

[7]  N. Lee,et al.  Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. , 2018, Thyroid : official journal of the American Thyroid Association.

[8]  S. Mandel,et al.  American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with , 2017, Thyroid : official journal of the American Thyroid Association.

[9]  D. McFadden,et al.  Thyroid cancer , 2016, The Lancet.

[10]  S. Davis,et al.  Radiotherapy in well‐differentiated thyroid cancer: is it underutilized? , 2016, ANZ journal of surgery.

[11]  P. Perros,et al.  Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines , 2016, The Journal of Laryngology & Otology.

[12]  E. Genden,et al.  External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society , 2016, Head & neck.

[13]  E. Kandil,et al.  Management of invasive well‐differentiated thyroid cancer: An American head and neck society consensus statement: AHNS consensus statement , 2014, Head & neck.

[14]  J. Thariat,et al.  Indications of external beam radiation therapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques. , 2013, Critical reviews in oncology/hematology.

[15]  N. Besic,et al.  Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma. , 2013, Thyroid : official journal of the American Thyroid Association.

[16]  Yoo Seok Jung,et al.  The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer , 2010, Radiation oncology.

[17]  N. Wada,et al.  Superior vena cava (SVC) reconstruction using autologous tissue in two cases of differentiated thyroid carcinoma presenting with SVC syndrome , 2009, World journal of surgical oncology.

[18]  M. Zelefsky,et al.  Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. , 2009, International journal of radiation oncology, biology, physics.

[19]  G. A. D. Carvalho,et al.  Carcinoma , 2020, Encyclopedia of Personality and Individual Differences.

[20]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[21]  T. Carling,et al.  Thyroid cancer. , 2014, Annual review of medicine.

[22]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[23]  N. Willich,et al.  Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer , 2009, Nuklearmedizin.

[24]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.